News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis’ Nomination Committee for the 2024 Annual General Meeting

November 1, 2023

Stockholm, Sweden, November 1, 2023. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2024 Annual General Meeting (AGM) to be held on May 6, 2024.
The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on April 27, 2023, comprises the following members:
Peder Walberg, appointed by Cetoros AB
Peter Lindell, appointed by Cidro Förvaltning AB
James Brush, appointed by Frazier Life Sciences
Thomas Lönngren, Chairman of the Board of Directors, will co-opt to the Nomination Committee.
The Committee's assignment is to present proposals regarding Chairman and other members of the Board, as well as remuneration to the Board´s members, to the AGM. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals regarding the process to appoint the Nomination Committee to the AGM in 2024.
Shareholders who wish to submit proposals to the Nomination Committee can do so by email to (please label emails ‘Nomination Committee’). Proposals should be submitted no later than January 19, 2024.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10